News

In this episode, hosts discuss the collaboration between Dexcom and Oura Ring, expanded compatibility of Omnipod 5 with Freestyle Libre 2, and Simplera CGM integration with the InPen.

In the fifth and final video from this series, experts discuss future research priorities and opportunities in hidradenitis suppurativa.

In part 4 of our series, expert dermatologists discuss the safety profile of bimekizumab in HS relative to other disease states and trials.

In this video series segment, expert dermatologsts prove ide insight into the strengths and limitations of IL-17 A/F inhibition in HS.

Expert dermatologists discuss the role of IL-17 A/F inhibition in the management of hidradenitis suppurativa.

In this 5-part, expert-led series, a pair of dermatologists break down how the FDA approval of bimekizumab impacts the treatment landscape of HS.

These data highlight some of the most notable findings related to airline travel issues among those with food allergies or with family members with such allergies.

A new study showed patients with MASLD have fragmented nocturnal sleep with frequent awakenings per night and a session on healthy sleep habits did not improve sleep parameters.

Phase 1/2 data prompted the RMAT designation for HLHS shortly after Mesoblast announced positive phase 3 data for HFrEF.

Greg Duck, PA-C shared insights from his CAPP 2024 presentation on tailoring medical management and effective treatment of methamphetamine-induced cardiomyopathy.

This month in review spotlights GI pipeline updates and news from the 2024 NASPGHAN and ACG annual meetings.

The phase 3 OLYMPIA 1 study highlights the benefits among those with prurigo nodularis of targeting interleukin-31 signaling using nemolizumab.

Perspective from neurologists on the current and future applications for artificial intelligence across a bevy of neurologic conditions.

Trivedi and Lawitz review long-term data from the phase 3 open-label ASSURE study and explain what they add to our understanding of seladelpar for PBC.

Trivedi and Lawitz discuss what sets seladelpar apart from other PBC therapies in the rapidly evolving treatment landscape.

Trivedi and Lawitz discuss the clinical impact of having seladelpar as a second-line treatment option for patients with PBC.

Trivedi and Lawitz discuss seladelpar’s mechanism of action and its use as a second-line therapy in PBC.

A study revealed that people who are older, uneducated, unemployed, below the poverty line, publicly insured, rural, and male did not increase in psychotherapy use from 2018 to 2021.

Dexamethasone treatment was linked to worse clinical outcomes in patients with sickle cell disease hospitalized for COVID-19.

This pooled analysis of 3-year data yielded positive efficacy and safety findings for deucravacitinib treatment of those with psoriasis.

The phase 2 study of a bemnifosbuvir and ruzasvir regimen for the treatment of HCV met both primary endpoints for safety and SVR 12 weeks post-treatment.

Data from SURMOUNT-5, a head-to-head trial, demonstrate tirzepatide offered greater weight loss benefits than semaglutide.

This month in review spotlights FDA news, new clinical trial data, and HCPLive’s coverage of the NASPGHAN 2024 annual meeting and AASLD The Liver Meeting.

Previous ASA guidance recommended holding GLP-1 RAs in the perioperative period, but new 2024 multisociety guidance suggests a risk-based approach.

In this iteration of the Month in Review series, a list of highlighted stories in the allergy and immunology space covered in the month of November is provided.

Anemia in heart failure with preserved ejection fraction was linked to right ventricular dysfunction in an analysis of more than 1000 patients in China.

Intra-Cellular Therapies announced they submitted a supplemental New Drug Application to the FDA for lumateperone (CAPLYTA) as an adjunctive therapy to antidepressants for MDD.

An overview and landing page for future installments from HCPLive's 8th annual This Year in Medicine Series.